Skip to main content

Table 3 Baseline population characteristics and primary outcome results

From: Heterogeneity amongst GLP-1 RA cardiovascular outcome trials results: can definition of established cardiovascular disease be the missing link?

  ELIXA [22] LEADER [24] SUSTAIN-6 [25] EXSCEL [27, 28] Harmony Outcomes [30] PIONEER 6 [32] REWIND [34]
N 6068 9340 3297 14,752 9463 3183 9901
Female 30.7% 35.7% 39.3% 38.0% 30.6% 31.6% 46.3%
Age (mean) 60.3 years 64.2 years 64.6 years 62.7 years 62.7 years 66.1 years 66.2 years
HbA1c (mean) 7.7% 8.7% 8.7% 8.0% 8.7% 8.2% 7.2%
Diabetes duration 9.3 years 12.8 years 13.9 years 12.0 years 13.8 years 14.9 years 9.5 years
eCVD
(according to each study’s definition)
100% (ACS) 81.3% 83.0% 73.1% 100% 84.6% 31.5%
HF (NYHA I-III)   17.8% 23.6% 16.2% 20.2%   8.6%
CKD (eGFR < 60 mL/min/1.73 m2) 23.2% 24.7% 28.5% 18.6% 22.6% 26.9% 22.2%
Follow-up (median) 2.1 years 3.8 years 2.1 years 3.2 years 1.5 years 1.3 years 5.4 years
  1. CKD chronic kidney disease, eCVD established cardiovascular disease, eGFR estimated glomerular filtration rate, HbA1c haemoglobin A1c (glycated haemoglobin), HF heart failure, NYHA New York Heart Association classification